GC Aesthetics ® Launches YOUTHLY™: A New Era for Breast Implants in China
17.9.2024 19:10:00 EEST | Business Wire | Press release
GC Aesthetics® (GCA), a leading medical technology company committed to advancing women’s health through innovative aesthetic and reconstructive breast solutions, is excited to announce the launch of the YOUTHLY™ brand in China, featuring its latest breast implant innovations: PERLE™, Luna XT™, and the latest version of The Round Collection™, 100% filled.
In an exclusive partnership with G&S Group, YOUTHLY™—handmade in France and the UK—will offer premium silicone breast implants to women and plastic surgeons across China.
China, the second-largest market in the world, has been a strategic focus for GC Aesthetics in recent years. The aesthetics market is projected to grow by 15% annually, reaching a staggering 200 billion yuan ($27.6 billion). GCA is proud to support and offer its innovative, high-quality solutions dedicated to women’s aesthetics healthcare (augmentation and reconstruction).
The YOUTHLY™ portfolio—The Round Collection™ 100% filled, PERLE™, and Luna XT™—caters to a range of patient needs, from natural and soft appearances to fuller, bolder looks.
The Round Collection™ 100% filled is GCA’s best-seller globally, with a proven high patient satisfaction rate backed by 10 years of clinical data.
PERLE™—newly launched in Europe and Latin America—has embedded GCA’s 40+ years of experience, offering a unique, soft, and natural breast implant with proven safety and efficacy based on an initial 3-year study.
Luna XT™ introduces a state-of-the-art option for women undergoing breast reconstruction, featuring a unique combination of a microtextured surface, highly cohesive silicone gel, and a high-performance shell for optimal, natural results.
Carlos Reis Pinto, CEO of GC Aesthetics®, stated: “Through the YOUTHLY brand, GCA wants to propose multiple innovative alternatives to Chinese plastic surgeons and patients. My goal is to continue investing and offering premium solutions that are aligned with our commitment to patients and surgeons: 'A Confident Choice for Life™,' covered by a unique lifetime warranty. We’re excited for the future and will soon launch YOUTHLY across the Asia-Pacific region.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917009200/en/
Contacts
press@gcaesthetics.com
+353 (0)1 293 3836
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Parse Biosciences and Nomic Announce 100 Million Cell, Multimodal AI-ready Dataset for Immune Biology29.10.2026 14:00:00 EET | Press release
Parse Biosciences, the leading provider of scalable and accessible single-cell sequencing and a QIAGEN company, and Nomic Bio, a leader in high throughput proteomic profiling, today announced their partnership to generate Cascade, a 100 Million cell foundational dataset to understand the human immune response. The dataset's scale and depth will give pharma partners cellular- and protein-level insight into immune biology, accelerating their ability to identify and validate new drug targets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029559438/en/ Cascade has already drawn foundational partner commitments from leading pharmaceutical and biotechnology companies, including GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine, underscoring the demand for large-scale, multimodal immune data in drug discovery. Cascade is a multimodal, perturbation dataset that captures how immune cells respond to treatment across multiple ti
CSC Named Winner of the Top InfoSec Innovator Award for Most Innovative DNS Security29.10.2026 14:00:00 EET | Press release
CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and Domain Name System (DNS) threats, today announced that its Subdomain Monitoring solution took top honors for Most Innovative DNS Security in Cyber Defense Magazine’s 2026 Top InfoSec Innovator Awards. CSC introduced Subdomain Monitoring after analyzing close to half a million DNS records and finding that many companies were exposed to subdomain takeovers due to dangling DNS. CSC’s solution helps enterprises reduce this risk and secure their online ecosystems. It was the first and only technology on the market to ease the burden of tracking and maintaining DNS records and purging unused zone records to prevent subdomain hijacking. Subdomain Monitoring, powered by CSC’s one-of-a-kind DomainSecSM threat intelligence platform, alerts DNS administrators and security engineers when it detects changes to their zone records. It also provides context on those changes, delivering greater visibility
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union29.10.2026 13:27:00 EET | Press release
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinuation remains a persistent challenge in lipid management.1,2 Across both primary and secondary prevention, a significant number of patients at high and very high CV risk do not reach their guideline-recommended LDL-C goals, often due to the complexity and pill burden of taking multiple medications.2 The applications cover two single-pill combinations of three established lipid-lowering agents: bempedoic acid with ezetimibe and atorvastatin, and bempedoic acid with ezetimibe and rosuvastatin.3 Multiple statin dose options of each of these
NIQ and Google Partner to Advance Agentic Commerce29.10.2026 12:45:00 EET | Press release
Today, NielsenIQ (NYSE: NIQ) and Google announced a broad collaboration to advance agentic commerce, aiming to bring NIQ’s global retail and product intelligence together with Google’s AI commerce ecosystem to improve product discovery and local availability. NIQ and Google are looking to complement Google's extensive Shopping Graph of more than 60 billion product listings with NIQ’s Commerce Intelligence. NIQ is also naming Google Cloud as a primary AI and cloud services provider, and plans to deploy Gemini for business across its global workforce. As AI evolves from helping consumers discover products to recommending and purchasing them, brands and retailers increasingly rely on trusted product information, real-world availability, and measurement. The partnership is designed to help make agentic commerce even more reliable and measurable, combining NIQ’s The Full View™ of consumer and retail intelligence with the scale and AI capabilities of Google Cloud and Gemini for business. The
TradeStation Europe Expands Options Capability, Including Extended-Hours Trading29.10.2026 12:43:00 EET | Press release
TradeStation Europe B.V. (“TradeStation Europe”), the recently licensed European brokerage subsidiary of TradeStation Group, Inc. (“TradeStation”), today announced a round of product updates, including extended-hours options trading, along with reduced options and equities pricing, new single-stock option spreads and expanded intraday trading to enhance the offering for retail and institutional traders across the Netherlands and the European Economic Area (EEA). Extended-hours options trading is now live. Clients can trade eligible equity options during a pre-market session from 7:30 a.m. to 9:25 a.m. ET and an extended curb session from 4:00 p.m. to 4:15 p.m. ET. The launch follows Cboe Global Markets, Inc.’s (Cboe: CBOE) introduction of extended trading hours for options on 24 individual stocks and five ETFs, expanding access to some of the most actively traded and liquid single-stock options outside of the regular U.S. trading session. The enhancement expands access beyond tradition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom